Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.35 |
| ▸ | PPARG | P37231 | 6/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3868206 | 0.87 | HTR2A (0.30) | — | |
| SCHEMBL11661901 | 0.82 | ACHE (0.32) | — | |
| SCHEMBL11850956 | 0.80 | — | — | |
| SCHEMBL11661015 | 0.78 | KCNE1 (0.32) | — | |
| SCHEMBL2944071 | 0.75 | PTGDR2 (0.40) | PTGDR2FFAR4 | |
| SCHEMBL11853875 | 0.70 | POLB (0.33) | PTGDR2 | |
| SCHEMBL11664241 | 0.69 | ACHE (0.32) | — | |
| SCHEMBL8054574 | 0.67 | AKR1C3 (0.36) | PTGDR2 | |
| SCHEMBL1452653 | 0.67 | KDM1A (0.31) | — | |
| SCHEMBL1452157 | 0.67 | KDM1A (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0206241-B1 | PROCESS FOR THE PREPARATION OF CIS-5-FLUORO-2-METHYL-1-(4-METHYLTHIOBENZYLIDENE)-INDENE-3-ACETIC ACID | ZAMBON S.p.A. (IT) | 1989-04-19 | — | — | EP | claimed |
| EP-0206241-A1 | Process for the preparation of cis-5-fluoro-2-methyl-1-(4-methylthiobenzylidene)-indene-3-acetic acid | ZAMBON S.p.A. (IT) | 1986-12-30 | — | — | EP | claimed |
| EP-3233794-B1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS LLC (US) | 2023-02-01 | — | — | EP | disclosed |
| US-20220315553-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS, LLC (US) | 2022-10-06 | — | — | US | disclosed |
| US-11198679-B2 | Method of treating or preventing Ras-mediated diseases | ADT PHARMACEUTICALS, LLC (US) | 2021-12-14 | — | — | US | disclosed |
| US-11130744-B2 | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | ADT PHARMACEUTICALS, LLC (US) | 2021-09-28 | — | — | US | disclosed |
| CN-107466232-B | Methods of treating or preventing RAS-mediated diseases | ADT制药有限责任公司 | 2021-06-29 | — | — | CN | disclosed |
| US-10981886-B2 | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | ADT PHARMACEUTICALS, LLC (US) | 2021-04-20 | — | — | US | disclosed |
| US-10975054-B2 | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | ADT PHARMACEUTICALS, LLC (US) | 2021-04-13 | — | — | US | disclosed |
| CN-112047909-A | Indenyl compound, pharmaceutical composition and medical application thereof | ADT制药有限责任公司 | 2020-12-08 | — | — | CN | disclosed |
| CN-107531615-B | Indenyl compound, pharmaceutical composition and medical application thereof | ADT制药有限责任公司 | 2020-09-04 | — | — | CN | disclosed |
| US-5643959-A | Method for treating patients with precancerous lesions by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof | CELL PATHWAYS, INC. (US) | 1997-07-01 | — | — | US | disclosed |
| EP-0723442-A4 | LACTONE COMPOUNDS FOR TREATING PATIENTS WITH PRECANCEROUS LESIONS | CELL PATHWAYS INC (US) | 1997-06-11 | — | — | EP | disclosed |
| EP-0723442-A1 | LACTONE COMPOUNDS FOR TREATING PATIENTS WITH PRECANCEROUS LESIONS | CELL PATHWAYS, INC. (US) | 1996-07-31 | — | — | EP | disclosed |
| WO-1996003987-A1 | LACTONE COMPOUNDS FOR TREATING PATIENTS WITH PRECANCEROUS LESIONS | CELL PATHWAYS, INC. (US) | 1996-02-15 | — | — | WO | disclosed |
| EP-0508586-B1 | Substituted indenyl compounds | FGN INC (US) | 1995-05-31 | — | — | EP | disclosed |
| US-5401774-A | Treatment of potentially cancerous growths | UNIVERSITY OF ARIZONA (US) | 1995-03-28 | — | — | US | disclosed |
| EP-0508586-A1 | Substituted indenyl compounds | FGN, INC. (US) | 1992-10-14 | — | — | EP | disclosed |
| EP-0485172-A2 | Esters and amides of substituted indenyl acetic acids | FGN, INC. (US) | 1992-05-13 | — | — | EP | disclosed |
| US-4087549-A | Sulphonic acid containing indenyl derivatives | MERCK & CO., INC. (US) | 1978-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315553-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | INSRR, INSR, BRCA1 | PTGDR2 288/4885AKR1B1 739/4885PPARG 2965/4885 |
| US-11198679-B2 | Method of treating or preventing Ras-mediated diseases | KRAS, NRAS, HRAS | PTGDR2 717/4885AKR1B1 326/4885PPARG 1654/4885 |
| US-11130744-B2 | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | INSRR, INSR, BRCA1 | PTGDR2 288/4885AKR1B1 739/4885PPARG 2965/4885 |
| US-10981886-B2 | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | INSRR, INSR, BRCA1 | PTGDR2 288/4885AKR1B1 739/4885PPARG 2965/4885 |
| US-10975054-B2 | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | INSRR, INSR, BRCA1 | PTGDR2 288/4885AKR1B1 739/4885PPARG 2965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.